TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079
CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311

11.08.2022

To,
BSE Limited
PhirozeJeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001

Dear Sir/Madam,

Scrip Code: 539428

Sub: Outcome of Board Meeting in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In continuation of our Letter dated 02th August, 2022 we wish to inform you that a meeting of the Board of Directors of the Company was held on **Thursday, 11th August, 2022** at **A 601, Floor No.6, Kailash Business Park, Veer Savarkar Marg, Vikroli - West, Mumbai – 400079 at 12.00 p.m.** and has transacted the following:-

1. Considered and approvedUn-Audited Financial Results (Standalone & Consolidated) for the quarterended on 30th June 2022 and took note of Limited Review Report thereon, in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015;

The meeting of Board of Directors commenced at 12.00 p.m. and concluded at 2.00 p.m.

This is for your information and record.

Thanking you.
For Tejnaksh Healthcare Limited

Rawandale

Dr. Ashish V. Rawandale
Managing Director
DIN:- 02005733

Limited Review Report on unaudited Standalone Financial Results of Tejnaksh Healthcare Limited for the quarter ended 30 June 2022 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Tejnaksh Healthcare Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Tejnaksh Healthcare Limited ("the Company") for the quarter ended June 30, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Attention is drawn to the fact that the figures for the three months ended 31 March 2022 as reported in these unaudited standalone financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally

P. D. DALAL & CO. Chartered Accountants

102, B Wing, Lake Florence, Phase I, Adi Shankaracharya Marg, Powai, Mumbai - 400 076 Maharashtra India
Email : auditpdd@gmail.com

accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **P.D.Dalal & Co.**
Chartered Accountants
ICAI Firm Registration No.102047W

(Aashish S. Kakaria)
Partner
Membership No.102915
Mumbai
11th August, 2022
UDIN: 22102915AOUKEE9479

TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079
CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE, 2022

Sl.No.	Particulars	Quarter Ended			Year Ended
		June 30,2022	March 31,2022	June 30,2021	March 31,2022
		(Unaudited)	(Refer Note 4)	(Unaudited)	(Audited)
1	**REVENUE**				
(a)	Revenue from operations (net)	185.77	175.94	233.43	811.78
(b)	Other income	4.35	5.40	3.02	13.22
	Total Revenue (I)	190.12	181.33	236.45	825.00
2	**EXPENSES**				
(a)	Purchases of stock-in-trade	16.57	14.49	25.48	77.68
(b)	Changes in inventories of Stock-in-Trade	2.68	(2.84)	4.98	(7.28)
(c)	Employee benefits expense	17.69	16.53	17.77	68.95
(d)	Finance costs	13.52	19.09	7.74	47.33
(e)	Depreciation and amortization expense	19.62	16.41	14.21	59.16
(f)	Other expenses	53.11	59.83	64.52	242.12
	Total Expenses (II)	123.20	123.51	134.70	487.96
3	**Profit before tax (I) - (II)**	66.92	57.82	101.75	337.04
4	**Tax expense:**				
(a)	Current tax	11.13	11.82	23.55	76.87
(b)	Deferred tax	5.71	3.06	1.84	8.29
	Total Tax Expenses	16.84	14.88	25.39	85.16
5	**Profit for the Period**	50.08	42.94	76.36	251.88
6	**OTHER COMPREHENSIVE INCOME**				
	A. Other Comprehensive income not to be reclassified to profit and loss in subsequent periods:				
	Actuarial gain / (loss) on liabilities	0.29	0.15	-	1.14
	Income tax effect	(0.07)	(0.04)	-	(0.29)
	B. Other Comprehensive income to be reclassified to profit and loss in subsequent periods:	-	-	-	
	Other Comprehensive income for the period, net of tax	0.21	0.11	-	0.85
	TOTAL COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX	50.29	43.06	76.36	252.74
7	**Paid up Equity Share Capital (Face value Rs 10/- each.)**	101.57	101.57	101.57	101.57
8	**Basic and Diluted earnings per share (INR)**	0.49	0.42	0.75	2.48

Notes:

1) The Statement of unaudited standalone financial results ('the Statement') of Tejnaksh Healthcare Limited ('the Company') for the quarter ended June 30, 2022 has been reviewed by the Audit Risk and Compliance Committee and approved by the Board of Directors on August 11, 2022. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.

2) The Statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

3) The Company's operating segment is 'Medical and Healthcare Services. Since the Company has a single operating segment. disclosure pertaining to segments as per Regulation 33(1)(c) read with clause (L) of Part A of Schedule IV of the SEBI Regulations is not applicable.

4) The figures of the last quarter are the balancing figures between audited figures in respect of full financial year and the published year to date figures upto the end of the third quarter of the financial year.

5) The figures for the corresponding previous period have been regrouped / reclassified wherever necessary, to make them comparable.

For and on behalf of board of Directors
Tejnaksh Healthcare Limited

(Dr. A.V. Rawandale)
Managing Director
DIN: 02005733

Mumbai
August 11, 2022

Tejnaksh Healthcare Limited MUMBAI

Limited Review Report on unaudited Consolidated Financial Results of Tejnaksh Healthcare Limited for the quarter ended 30 June 2022 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Tejnaksh Healthcare Limited

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of Tejnaksh Healthcare Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parents Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34. (Ind AS 34) 'Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410. Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial infom1ation consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. The Statement includes results of the Holding Company- Tejnaksh Healthcare Limited and subsidiary Company - Tej Vedaant Healthcare Private Limited.

5. The accompanying unaudited consolidated financial results includes unaudited interim financial results and other unaudited financial information in respect of its subsidiary which have been approved and furnished to us by the management. Our conclusion on the Statement is not modified in respect of the above matter.

6. Attention is drawn to the fact that the figures for the three months ended 31 March 2022 as reported in these unaudited consolidated financial results are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the

P.D. DALAL & CO. Chartered Accountants

102, B Wing, Lake Florence, Phase I, Adi Shankaracharya Marg, Powai, Mumbai - 400 076 Maharashtra India Email : auditpdd@gmail.com

end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

7. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **P.D.Dalal & Co.**
Chartered Accountants
ICAI Firm Registration No.102047W

(Aashish S. Kakaria)
Partner
Membership No.102915
Mumbai
11th August, 2022
UDIN: 22102915AOUKGG8713

TEJNAKSH HEALTHCARE LIMITED

Regd. Add. : A 601, Floor No. 6, Kailash Business Park, Veer Savarkar Marg, Vikroli (W), Mumbai - 400079
CIN : L85100MH2008PLC179034, Email : instituteofurology@gmail.com
Website : www.tejnaksh.com | Tel No. : 022 - 2754 2311

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE, 2022

Sl.No.	Particulars	Quarter Ended			Year Ended
		June 30,2022	March 31,2022	June 30,2021	March 31,2022
		(Unaudited)	(Refer Note 4)	(Unaudited)	(Audited)
1	**REVENUE**				
(a)	Revenue from operations (net)	288.48	294.13	321.15	1,267.64
(b)	Other income	4.35	5.98	3.59	14.62
	Total Revenue (I)	**292.83**	**300.11**	**324.73**	**1,282.26**
2	**EXPENSES**				
(a)	Purchases of stock-in-trade	33.38	33.14	37.82	143.77
(b)	Changes in inventories of Stock-in-Trade	(1.05)	(3.52)	9.66	(2.45)
(c)	Employee benefits expense	32.20	31.02	33.26	131.25
(d)	Finance costs	13.52	19.09	7.74	47.33
(e)	Depreciation and amortization expense	21.66	18.42	15.88	66.57
(f)	Other expenses	115.56	124.13	119.20	519.67
	Total Expenses (II)	**215.27**	**222.27**	**223.57**	**906.13**
3	**Profit before tax (I) - (II)**	**77.55**	**77.84**	**101.17**	**376.13**
4	**Tax expense:**				
(a)	Current tax	13.82	16.69	23.55	86.51
(b)	Deferred tax	5.69	3.23	1.82	8.48
	Total Tax Expenses	19.52	19.92	25.37	94.99
5	**Profit for the year**	58.04	57.92	75.80	281.14
6	**OTHER COMPREHENSIVE INCOME**				
	A. Other Comprehensive income not to be reclassified to profit and loss in subsequent periods:				
	Actuarial gain / (loss) on liabilities	0.80	2.14	-	3.20
	Income tax effect	(0.20)	(0.54)	-	(0.81)
	B. Other Comprehensive income to be reclassified to profit and loss in subsequent periods:	-	-	-	-
	Other Comprehensive income for the year, net of tax	0.60	1.60	-	2.40
	TOTAL COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX	58.63	59.52	75.80	283.54
7	**Profit for the year attributable to:**				
	Equity holders of the parent	56.05	54.18	75.94	272.38
	Non-controlling interests	1.99	3.74	(0.14)	8.76

8	**Other comprehensive income for the year attributable to:**				
	Equity holders of the parent	0.50	1.23	-	2.01
	Non-controlling interests	0.10	0.37	-	0.39
9	**Total comprehensive income for the year attributable to:**				
	Equity holders of the parent	56.55	55.41	75.94	274.39
	Non-controlling interests	2.09	4.12	(0.14)	9.15
10	**Paid up Equity Share Capital (Face value Rs 10/- each.)**	101.57	101.57	101.57	101.57
11	**Basic and Diluted earnings per share (INR)**	0.55	0.53	0.75	2.68

Notes:

1) The Statement of unaudited consolidated financial results ('the Statement') of Tejnaksh Healthcare Limited (the'Parent'/ 'Group') and its subsidiaries (together referred to as the 'Group') for the quarter ended June 30, 2022 has been reviewed by the Audit Risk and Compliance Committee and approved by the Board of Directors on August 11, 2022. The Statutory Auditors of the Group have carried out a Limited Review of the aforesaid results.

2) The Statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim financial Reporting", prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

3) The Group's operating segment is 'Medical and Healthcare Services. Since the Group has a single operating segment. disclosure pertaining to segments as per Regulation 33(1)(c) read with clause (L) of Part A of Schedule IV of the SEBI Regulations is not applicable.

4) The figures of the last quarter are the balancing figures between audited figures in respect of full financial year and the published year to date figures upto the end of the third quarter of the financial year.

5) The figures for the corresponding previous period have been regrouped / reclassified wherever necessary, to make them comparable.

For and on behalf of board of Directors
Tejnaksh Healthcare Limited

(Dr. A.V. Rawandale)
Managing Director
DIN: 02005733

Tejnaksh Healthcare Limited MUMBAI

Mumbai
August 11, 2022